Ardea Biosciences Inc

Ardea Biosciences — Corporate Update (September 2007)

42 slides from Ardea Biosciences's corporate update, Sep 4, 2007

  1. Slide 1: Company Update September 2007

    Company Update September 2007

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results

  3. Slide 3: Ardea Investment Highlights

    3 Ardea Investment Highlights Focused on design and development of small-molecule drugs for viral diseases, cancer and inflammation Targeting established, multibillion-dollar markets with molecules that we believe: offer significant enhancements over standard of care can be quickly and cost-effectiv

  4. Slide 4: Management Team

    4 President, Agouron R&D; SVP, Pfizer Global R&D; President, NAPO Pharmaceuticals VP, Regulatory Affairs, Exelixis; Senior Director Regulatory Affairs, Agouron VP, Research - Therapeutic Head, Pfizer Global Oncology; VP, Oncology Research Division, Agouron; Fogarty Fellow, NCI SVP, BD & Strategic Al

  5. Slide 5: Research & Development

    5 Research & Development Core Research Capabilities X-ray Chrystallography/SBDD Medicinal Chemistry Virology, Oncology & Neurology High throughput screening Development Capabilities ADME/Toxicology/GLP Analytical Formulation development Kilogram chemical synthesis capacity, small scale GMP facility

  6. Slide 6: Ardea Pipeline

    6 Discovery Preclinical Phase 0/1 Phase 3 Phase 2 RDEA119 (MEKI) 2nd NNRTI 2nd MEKI Cancer/Inflam RGB FF (CNS) RDEA806 (NNRTI) Viral Diseases First Milestone Payment Received IND 2H07 FIH 4Q07 FIH 4Q07 4Q07 Phase 2a Ardea Pipeline

  7. Slide 7: Company Background

    7 Company Background Acquired R&D programs from Valeant and hired new management in December 2006 Two interesting pre-IND candidates RDEA806 NNRTI for HIV RDEA119 MEK inhibitor for cancer Several back-up compounds in each class Strong intellectual property position Fully equipped laboratories and in

  8. Slide 8: Terms of Valeant Deal

    8 Terms of Valeant Deal Potential milestone payments $25 million for first NNRTI $17 million for first MEK inhibitor First payment due after clinical proof of concept More than half of total payments due after regulatory approval Pay once, regardless of # of compounds/indications developed Royalty r

  9. Slide 9: HIV Program

    Ardea (Biosciences

  10. Slide 10: HIV Market Opportunity

    10 HIV Market Opportunity Maturing $8+ billion market Focus on safe, convenient therapies Continuing need for new treatments Limited number of safe and convenient treatments for resistant virus Increasing number of new seroconverters have resistant strains (many to efavirenz) No current treatment re

  11. Slide 11: HIV Market Opportunity

    11 HIV Market Opportunity Three primary classes of therapies: 10 approved protease inhibitors (PIs), 11 nucleosides (NRTIs; single agents and combinations), but only 3 approved non-nucleosides (NNRTIs); one is not actively promoted Current leader - first-line treatment is efavirenz (Sustiva(r)) with

  12. Slide 12: Desired NNRTI Target Product Profile

    12 Highly active against efavirenz-resistant strains (single- and double- mutants) High genetic barrier to resistance Better safety profile than efavirenz: Reduced CNS toxicity Improved lipid profile Easy to formulate in combination pill Long half-life: Once daily for first-line Once or twice daily

  13. Slide 13: Antiviral Activity

    13 Antiviral Activity Virus Prevalence* RDEA806 RDEA806 Efavirenz Efavirenz Virus Prevalence* EC50 (nM) FC** EC50 (nM) FC** wt 3.0 0.4 K103N 88.5% 2.3 0.76 5.9 16 K103N-P225H 32.7% 10.3 3.4 77.9 212 K103N-V108I 28.8% 2.0 0.67 15.3 42 K103N-K101Q 16.3% 11.6 3.8 21.8 60 K103N-L100I 10.6% 1.6 0.53 636

  14. Slide 14: Mutation Selection and Time Course of Viral Breakthrough

    14 Days in Selection Fold Change over EC50 K104E-E138K- V179D-F227L-T240I K104E-E138K- T240I K103N- V106A- K219E-F227L- K512E K103N-L100I- A371T K103N-L100I K103N-V106A EFV- K103N EFV-WT 806-WT Mutation Selection and Time Course of Viral Breakthrough RDEA806 has a much higher barrier to resistance t

  15. Slide 15: RDEA806-101 Single Ascending Dose Study

    RDEA806-101 Single Ascending Dose (SAD) Study Full details will be presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): Abstract #1609: "Safety and Pharmacokinetics of Ascending Single Oral Doses of RDEA806, a Novel HIV NNRTI, in Healthy Volunteers"

  16. Slide 16: Phase 1 SAD and MAD Studies

    16 Phase 1 SAD and MAD Studies SAD Single ascending doses from 50 mg to 600 mg Food effect Impact of ritonavir on RDEA806 Evaluation of two formulations MAD 300 mg BID 500 mg BID 400 mg BID (improved formulation) 16

  17. Slide 17: Conclusions from Phase 1

    17 Conclusions from Phase 1 RDEA806 was safe and well tolerated at all doses tested No serious adverse events No grade 3 or 4 adverse events reported No clinically significant laboratory or ECG abnormalities noted AUC increased linearly with dose Terminal half-life at highest doses was 11-13 hr Impr

  18. Slide 18: RDEA806 Compared to the Target Product Profile

    18 RDEA806 Compared to the Target Product Profile From preclinical and Phase 1 results to date, RDEA806 appears to be a good candidate to meet our desired Target Product Profile Highly active against efavirenz-resistant strains (single- and double- mutants) High genetic barrier to resistance Better

  19. Slide 19: Planned Phase 2a HIV PoC Study

    19 Planned Phase 2a HIV PoC Study Study RDEA806-201 ART-Naive Monotherapy RDEA806-201 ART-Naive Monotherapy 1^ Endpoint Change from baseline in plasma VL Change from baseline in plasma VL 2^ Endpoints VL decay rate, CD4 and CD8 changes, PK/PD, safety, tolerability, genotypic and phenotypic resistanc

  20. Slide 20: NNRTI Follow-on Series

    20 NNRTI Follow-on Series Different structural class than RDEA806 Appears to be more potent, with greater coverage of resistant strains Potentially longer half-life Goal: conduct micro-dosing study with 1-2 compounds from this class in 4Q07 to confirm pharmacokinetics 20 EC50 (nM) for Antiviral Acti

  21. Slide 21: Competitive Landscape

    21 Competitive Landscape Other companies have also identified the opportunity to develop new NNRTIs: Tibotec/J&J TMC125 - filed for FDA approval July 2007 Significant drug interactions and rash TMC278 - Phase 2 data presented at CROI 2/07 Pfizer UK-453,061 - Phase 2a presented at IAS in 7/07 Idenix

  22. Slide 22: Cancer Program

    Cancer Program Ardea (Biosciences

  23. Slide 23: Cancer Market Opportunity

    Cancer Market Opportunity Cancer affects > 1 in 3 people during lifetime Common tumors: lung, breast, colon and prostate Global incidence forecast to grow Aging population / policies to increase detection/treatment Oncology market more than doubled in the past five years Global oncology market growi

  24. Slide 24: MEK as Anticancer Target

    Nexavar MEK Ras Raf c-Myc Herceptin, Erbitux Proliferation Angiogenesis Differentiation Apoptosis cPLA2 PDE4 MNK1/2 Elk-1 MAPKAPK1/3 ARRY-142886 (Ph 2) PD0325901 (Ph 2?) XL518 (Ph 1) RDEA119 RTK Bcl-2 Mcl-1 c-Jun Tarceva GF ERK2 ERK2 MEK as Anticancer Target 24

  25. Slide 25: MEK as Anticancer Target

    MEK as Anticancer Target RAS-RAF-MEK-ERK activation common in human cancer One of two major signaling pathways: MEK/ERK vs. PI3K/AKT RAS activating mutations lead to increased signaling through pathway Colon (~50%) Lung (~30%) Pancreas (~90%) BRAF activating mutations sensitize cancer cell lines to

  26. Slide 26: Competitive Landscape

    26 Competitive Landscape Pfizer Innovator of MEK inhibitors Second generation compound, PD-325901, demonstrated activity in Phase 1, but Phase 2 slowed due to toxicity Array/AstraZeneca December 2003 partnership ARRY-866/AZ-6244 in Phase 2 for melanoma, colon CA, pancreatic CA, and NSCLC ARRY-162/AZ

  27. Slide 27: RDEA119 is a Potent, Highly Specific MEKI

    RDEA119 is a Potent, Highly Specific MEKI % Inhibition 1 6 11 16 21 26 31 0 20 40 60 80 100 1 6 11 16 21 26 31 MEK1 & MEK2 MEK1 & MEK2 0 20 40 60 80 100 Ron SRC RDEA119 PD-325901 (Pfizer) >100-fold selectivity in kinase panel of 205 enzymes at 10 µM** MEK1/2 Enzyme IC50 17-50 nM Cellular pERK EC50 2

  28. Slide 28: Colo205 Human Colon Cancer Xenograft

    28 Colo205 Human Colon Cancer Xenograft 0 10 20 30 40 Days Tumor volume (mm3) Vehicle RDEA119 25mg/kg RDEA119 50mg/kg RDEA119 100mg/kg Dosing Period 0 200 400 600 800 1000 1200 Lowest dose tested, 25 mg/kg, produced 7 PRs and 2 CRs out of 9 mice; 2 were tumor free at end of study

  29. Slide 29: A375 Human Melanoma Xenograft

    A375 Human Melanoma Xenograft 25 mg/kg QD 50 mg/kg QD Vehicle Dosing Period 29 Days Percent Survival

  30. Slide 30: Assessment of Brain Penetration

    Assessment of Brain Penetration 30 RDEA119 PD-325901 RDEA119 has less potential for CNS toxicity Efflux ratio from MDR1-MDCK permeability model tested side-by-side Efflux Ratio Steady-State Concentrations after 5 mg/kg Oral Dosing in Rats

  31. Slide 31: RDEA119 Pharmacokinetic Profile

    RDEA119 Pharmacokinetic Profile Excellent PK profiles in rats, dogs and monkeys Orally bioavailable with the potential for once or twice daily dosing Extensive enterohepatic recirculation, gives opportunity to target the GI tract Low brain penetration potential, with an efflux ratio of 20, versus 10

  32. Slide 32: Planned Phase 1 Multiple-Dose PK/PD Study in Advanced Cancer Patients

    32 Planned Phase 1 Multiple-Dose PK/PD Study in Advanced Cancer Patients Study RDEA119-201 Advanced Cancer Patients 1^ Endpoint Safety, tolerability, PK Safety, tolerability, PK 2^ Endpoints Pharmacodynamic (PD) measures: pERK, Ki67, Nras, Kras and Braf mutations; Antitumor activity by CT scan Pharm

  33. Slide 33: Inflammation Program

    Inflammation Program Ardea\) Biosciences 33

  34. Slide 34: Inflammation Commercial Opportunity

    34 Inflammation Commercial Opportunity Inflammatory Bowel Disease (IBD) Currently affects 1 million Americans, with 30,000 new cases/yr Clinical trials can be conducted rapidly Rheumatoid Arthritis (RA) Afflicts approximately 1% of the world's population Approximately 2.1 million Americans Psoriasis

  35. Slide 35: Inhibition of Cytokines and Preclinical Results

    35 Inhibition of Cytokines and Preclinical Results* EC50 (nM) for Cytokine Inhibition EC50 (nM) for Cytokine Inhibition EC50 (nM) for Cytokine Inhibition EC50 (nM) for Cytokine Inhibition EC50 (nM) for Cytokine Inhibition EC50 (nM) for Cytokine Inhibition EC50 (nM) for Cytokine Inhibition IL-1^ IL-6

  36. Slide 36: Activity of RDEA119 in TNBS-induced Colitis in BALB/c Mice

    Activity of RDEA119 in TNBS-induced Colitis in BALB/c Mice RDEA119 administered orally for 5 days significantly reduced the colonic damage 36 Naive Vehicle 150 mg/kg Sulfasalazine 3 mg/kg RDEA119 10 mg/kg RDEA119 Macroscopic Damage Score *p < 0.01 **p < 0.001 vs. vehicle (n=10/group) Damage Score (M

  37. Slide 37: MEK Inhibitor Follow-on Series

    37 MEK Inhibitor Follow-on Series Different structural class than RDEA119 Appears to be more potent, with greater inhibition of cytokines Potentially longer half-life Goal: conduct micro-dosing study with a compound from this class in 4Q07 to confirm pharmacokinetics 37 EC50 (nM) for Cytokine Inhibi

  38. Slide 38: Efficacy of RDEA436 in Carrageenan Paw Edema Model

    Compounds dosed orally, 2 hr prior to carrageenan N = 6 male SD rats/treatment group *p < 0.01 Dunnett's test compared to vehicle 0% 40% 55% 66% 63% 38% RDEA436 has superior efficacy to maximally effective dose of indomethacin Efficacy of RDEA436 in Carrageenan Paw Edema Model 38

  39. Slide 39: Assessment of Brain Penetration

    Assessment of Brain Penetration 39 39 RDEA436 RDEA119 PD-325901 RDEA436 RDEA119 PD-325901 RDEA436 RDEA436 has efflux ratio of 96 vs 10 for PD-325901 Brain levels of RDEA436 were 16% of blood levels after oral dosing in rat vs. 69% for PD-325901; 4-fold safety advantage Efflux Ratio PD-325901 RDEA436

  40. Slide 40: Financial Position Summary

    Financial Position Summary Statement of Operations (In thousands, except per share data) Six Months Ended June 30, 2007 Revenue Operating expenses Other income $1,750 $11,857 $1,367 NET LOSS $(8,864) NET LOSS PER SHARE $(0.94) Currently 11.8 million shares outstanding Plan to end 2007 with $28-$32 m

  41. Slide 41: Anticipated Milestones for 2007-1H2008

    41 Anticipated Milestones for 2007-1H2008 Date Drug Candidate Event 9/18-19/2007 RDEA806 Four ICAAC Posters 2H07 RDEA119 Phase 1 start 4Q07 RDEA806 Phase 2a start 4Q07 NNRTI Follow-on FIH micro-dosing 4Q07 MEKI Follow-on FIH micro-dosing 1Q08 RDEA806 Phase 2a results 2Q08 RDEA806 Phase 2b start

  42. Slide 42: Ardea Investment Highlights

    42 Ardea Investment Highlights Focused on design and development of small-molecule drugs for viral diseases, cancer and inflammation Targeting established, multibillion-dollar markets Plan to have four molecules in humans this year Strong financial position and multiple partnering opportunities

Ardea Biosciences — Corporate Update (September 2007) on 6ix